225Ac-PSMA-I&T靶向α治疗晚期mCRPC的首个临床结果
该回顾性分析纳入14例晚期转移性去势抵抗性前列腺癌患者,其中11例曾接受阿比特龙或恩扎卢胺、化疗及177Lu-PSMA治疗。患者接受225Ac-PSMA-I&T治疗,中位剂量7.8 MBq,每两月一次。7例患者PSA下降≥50%,11例任何程度PSA下降;3例出现3级贫血,1例3级白细胞减少,5例新发1-2级口干。
要点
- 225Ac-PSMA-I&T在经多线治疗的晚期mCRPC中显示有前景的抗肿瘤效果。
- 7/14例患者PSA下降≥50%,11/14例任何程度PSA下降。
- 3级贫血3例,3级白细胞减少1例,新发1-2级口干5例。
核心结论
- 225Ac-PSMA-I&T靶向α治疗在晚期mCRPC中显示有前景的抗肿瘤效果,结果与225Ac-PSMA-617数据高度可比。
研究设计与样本
- 回顾性分析纳入14例接受225Ac-PSMA-I&T治疗的晚期mCRPC患者,其中11例有既往二线抗雄激素、化疗及177Lu-PSMA治疗史。
主要发现
- 基线PSA为112 ng/mL(范围20.5-818 ng/mL),最佳PSA应答(下降≥50%)见于7例,任何程度PSA下降见于11例,3例无PSA下降。
- 既往177Lu-PSMA治疗的11例亚组中,8例任何程度PSA下降,5例下降至少50%。
- 3级贫血见于3/14例(其中2例基线已有2级贫血),3级白细胞减少见于1例。
- 既往177Lu-PSMA后存在口干的8例患者接受TAT后口干无加重,新发1级或2级口干5例,1例无口干。
临床怎么用
- 对于经多线治疗失败的晚期mCRPC患者,225Ac-PSMA-I&T可作为潜在治疗选择,但需关注血液学毒性。
局限性
- 回顾性分析、样本量小(14例),需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of advanced metastatic castration-resistant prostate cancer after failure of approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA)-targeting β- and α-emitters have been introduced, with promising response rates. Here, we present the first-to our knowledge-clinical data for PSMA-targeted α-therapy (TAT) using 225Ac-PSMA imaging and therapy (I&T). Methods: Fourteen patients receiving 225Ac-PSMA-I&T were included in this retrospective analysis. Eleven of the 14 had prior second-line antiandrogen treatment with abiraterone or enzalutamide, prior chemotherapy, and prior 177Lu-PSMA treatment. Patients were treated at bimonthly intervals until progression or intolerable side effects. Prostate-specific antigen (PSA) was measured for response assessment. Hematologic and nonhematologic side effects were recorded according to the Common Terminology Criteria for Adverse Events, version 5.0. Results: Thirty-four cycles of 225Ac-PSMA-I&T were applied (median dose, 7.8 MBq; range, 6.0-8.5), with 1 cycle in 3 patients, 2 cycles in 7 patients, 4 cycles in 3 patients, and 5 cycles in 1 patient. No acute toxicity was observed during hospitalization. Baseline PSA was 112 ng/mL (range, 20.5-818 ng/mL). The best PSA response after TAT (a PSA decline ≥ 50%) was observed in 7 patients, and a PSA decline of any amount was observed in 11 patients. Three patients had no PSA decline at any time. A subgroup analysis of 11 patients with prior 177Lu-PSMA treatment showed any PSA decline in 8 patients and a decline of at least 50% in 5 patients. After TAT, grade 3 anemia was observed in 3 of the 14 patients, with 2 of them presenting with grade 2 anemia already at baseline. Grade 3 leukopenia was observed in 1 patient. Eight patients with preexisting xerostomia after 177Lu-PSMA showed no worsening after TAT. Newly diagnosed grade 1 or 2 xerostomia after TAT was observed in 5 patients. One patient reported no xerostomia at all. Conclusion: Our first clinical data for TAT using 225Ac-PSMA-I&T showed a promising antitumor effect in advanced metastatic castration-resistant prostate cancer. These results are highly comparable to data on 225Ac-PSMA-617 TAT.
引用
- Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients. J Nucl Med. 2020. PMID: 33008928. doi:10.2967/jnumed.120.251017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。